BIOTOSCANA INVESTMENTS S.A
Corporate Taxpayer’s ID (CNPJ/ME): 19,688,956/0001-56
L-1470 Luxembourg, 70 route d’Esch, Grand-Duché de Luxembourg
Legal representative in Brazil: Av. dos Imarés, 401, São Paulo, SP

NOTICE TO THE MARKET
UNIFIED TENDER OFFER

BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical
company in Latin America, hereby informs that a draft of the Offer Notice (Edital) that was submitted to
the Brazilian Securities and Exchange Commission (Comissão de Valores Mobiliários) (“CVM”) related to
the Unified Tender Offer process filed by 11718991 CANADA INC., a wholly owned subsidiary of Knight
Therapeutics Inc., as informed to the market and GBT’s shareholders in the Material Fact disclosed on
December 20, 2019, is available at Grupo Biotoscana website – http://ir.grupobiotoscana.com. The draft
of the Offer Notice (Edital) remains subject to CVM’s review.

The terms and conditions of the Unified Tender Offer remain as previously disclosed by Knight.

The Company will keep its shareholders and the market informed on the developments of the Unified
Tender Offer, in compliance with applicable regulation.

Montevideo, April 1, 2020

BIOTOSCANA INVESTMENTS S.A.
Claudio Coracini
Representante Legal in Brasil

Updated on 04/01/2020 at 11:28 pm